Podcasts about Sequencing

Episode 386 Show Notes Topic of the show: VFR Vectors to Final. Sponsored by SGAC Patron SA On this week's show, RH and AG discuss sequencing VFR's to a Charlie airport and the etiquette involved on both sides of the mic.  We also discuss a real life center controller sighting, confusing late night flying mistakes, and more of your awesome aviation feedback.  Links: https://youtu.be/Dml3O6Irmt0 Timely Feedback: 1. Army IP DS answers the radar altimeter question from last week, thanks! 2. Patron SRD answers the radar altimeter question also, thank you! 3. Patron BDM asks about controllers after an incident 4. Patron JAC sends a story about his first solo cross country Feedback 1. Patron TS discusses shift work as a submariner 2. Harrier the Bean sends several interactions with ATC 3. Patron SG sends audio about audio 4. Patron DDC talks night flying for IFR training 5. Patron DB talks about a recent Center tour Have a great week and thanks for listening!  Visit our website at OpposingBases.com You can support our show using Patreon or visiting our support page on the website.  Keep the feedback coming, it drives the show! Don't be shy, use the “Send Audio to AG and RH” button on the website and record an audio message. Or you can send us comments or questions to feedback@opposingbases.com.  Music bumpers by audionautix.com.  Third party audio provided by liveatc.net.  Legal Notice The views and opinions expressed on Opposing Bases Air Traffic Talk are for entertainment purposes only and do not represent the views, opinions, or official positions of the FAA, Penguin Airlines, or the United States Army.  Episodes shall not be recorded or transcribed without express written consent. For official guidance on laws, rules, and regulations, consult an aviation attorney or certified flight instructor.

In this episode of The Perceptive Photographer, I dive into the relationship between form and content in photography, especially when editing and sequencing a body of work. While a photo might carry personal meaning for me, I know it doesn't inherently hold that story for the viewer—it's their interpretation that brings it to life. That's why I encourage photographers to critically assess what's included and excluded in the frame to better communicate their intent.

Featuring an interview with Dr Lindsey Roeker, including the following topics: Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00) Safety of BTK inhibitors in older and frail patients with CLL (3:41) Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20) Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32) Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31) Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16) Sequencing, tolerability and future development involving pirtobrutinib (25:57) Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28) Clinical considerations in the management of Richter's transformation (38:14) Survival outcomes and quality of life for patients with CLL (41:02) Ongoing and future efforts to improve CLL treatment outcomes (45:01) CME information and select publications  

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: EZH2 Inhibitors for Follicular Lymphoma (FL) (0:00) Bruton Tyrosine Kinase Inhibitors for FL (5:43) Anti-CD19 Antibodies for FL (9:40) Other Novel Agents Under Clinical Development for FL (18:50) Case: A woman in her early 80s with multiple comorbidities and relapsed FL (23:06) Case: A man in his early 40s with high-risk progressive FL that did not achieve deep remission with prior therapy (27:07) Case: A woman in her early 70s with rheumatoid arthritis and relapsed FL (33:46) CME information and select publications

Featuring perspectives from Dr Paul E Oberstein and Dr Philip A Philip, including the following topics: Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Oberstein (0:00) Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr Philip(30:57) CME information and select publications

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Follicular Lymphoma (FL) (0:00) Case: A man in his late 60s with relapsed FL who received axicabtagene ciloleucel (axi-cel) but experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and chronic cytopenia (3:50) Published Clinical Data Involving Axi-cel (10:24) Case: A man in his mid 60s with multiple comorbidities and progressive FL who received tisagenlecleucel (tis-cel) (15:34) Published Clinical Data Involving Tis-cel (19:47) Case: A woman in her late 40s with multiple comorbidities and refractory FL who received lisocabtagene maraleucel (liso-cel) after prior mosunetuzumab (22:43) Published Clinical Data Involving Liso-cel (26:05) Incidence and Management of Toxicities Associated with CAR T-Cell Therapy (27:48) Sequencing Considerations and Ongoing Trials Involving CAR T-Cell Therapy (30:35) Practical Considerations and Referrals for CAR T-Cell Therapy Administration (31:59) CME information and select publications

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.

This episode teaches that innovation is born at the intersection of curiosity and persistence. Dr. Gudrun Stengel, co-founder and CEO of Alida Biosciences, reveals how her startup is transforming the landscape of RNA research through a novel technology called proximity barcoding. Dr. Stengel's story exemplifies the power of entrepreneurial spirit in driving scientific discovery, offering a glimpse into how one idea can reshape an entire field.At Alida Biosciences, Dr. Stengel and her team are pioneering new tools for detecting RNA modifications, a largely unexplored realm of epigenetics. Using their proximity barcoding platform, researchers can read multiple RNA modifications simultaneously, uncovering potential biomarkers and therapeutic targets for diseases like cancer, Alzheimer's, and diabetes. This technology bridges a critical gap in multiomics, allowing scientists to dive deeper into how epigenetic changes influence gene expression and cellular behavior.Beyond the lab, Dr. Stengel shares her experience as a first-time founder, balancing scientific rigor with startup life. From managing a team to fundraising, her journey underscores the importance of resilience, optimism, and maintaining a long-term vision. She also offers valuable advice for budding scientists, encouraging them to embrace challenges and remain persistent in the face of setbacks. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

In this thrilling installment of Impact Theory, Tom Bilyeu sits down with Ben Lamm, visionary founder and CEO of Colossal Biosciences, a company on a mission to reverse extinction and rewrite the future of conservation and synthetic biology. Ben and Tom dive deep into the mind-bending world of de-extinction, synthetic gene editing, and how the CRISPR revolution is not only unlocking the secrets of life—but also actively engineering it. In Part 1, get ready for a rollercoaster of concepts as Ben explains the technical magic behind gene editing, DNA synthesis, and multiplex genome editing. From the birth of the woolly mouse to the debated revival of dire wolves, Ben reveals the breakthroughs, challenges, and wild stories behind reviving extinct species. You'll learn how Colossal is using advanced computational biology, AI, and hands-on bioengineering to not only bring animals back but also reshape the future of healthcare, genetics, and ethical decision-making. This is part sci-fi, part practical science, and 100% mind-blowing. SHOWNOTES 00:00 – Kicking Off: The Mysteries of Editing Life 00:14 – Emergence of the CRISPR Revolution 01:31 – What Is DNA Synthesis and Multiplex Editing? 03:47 – The Woolly Mouse: Engineering Traits Across Species 07:54 – Breaking Down the Process: IVF, Screening, and Sequencing 09:24 – Mapping Genotype to Phenotype and Its Challenges 12:10 – Targeting Gene Edits: From Theory to Application in Health and Conservation 17:09 – From Hair Organoids to Building Mammoth Traits in Mice 24:41 – The Quest for a Universal Egg and Overcoming Cellular Barriers 26:17 – Artificial Wombs: The Next Frontier in Conservation and Science 31:12 – Scaling Conservation and Bridging to Human Healthcare FOLLOW BEN LAMM Twitter/X: @federallamm LinkedIn: Ben Lamm CHECK OUT OUR SPONSORS ButcherBox: Ready to level up your meals? Go to ⁠https://ButcherBox.com/impact⁠ to get $20 off your first box and FREE bacon for life with the Bilyeu Box! Vital Proteins: Get 20% off by going to ⁠https://www.vitalproteins.com⁠ and entering promo code IMPACT at check out Shopify: Sign up for your one-dollar-per-month trial period at ⁠https://shopify.com/impact⁠ Netsuite: Download the CFO's Guide to AI and Machine Learning at ⁠https://NetSuite.com/THEORY⁠ iTrust Capital: Use code IMPACTGO when you sign up and fund your account to get a $100 bonus at ⁠https://www.itrustcapital.com/tombilyeu⁠  Mint Mobile: If you like your money, Mint Mobile is for you. Shop plans at ⁠https://mintmobile.com/impact.⁠  DISCLAIMER: Upfront payment of $45 for 3-month 5 gigabyte plan required (equivalent to $15/mo.). New customer offer for first 3 months only, then full-price plan options available. Taxes & fees extra. See MINT MOBILE for details. What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business: join me here at ZERO TO FOUNDER SCALING a business: see if you qualify here. Get my battle-tested strategies and insights delivered weekly to your inbox: sign up here. ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** LISTEN TO IMPACT THEORY AD FREE + BONUS EPISODES on APPLE PODCASTS: apple.co/impacttheory ********************************************************************** FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu Learn more about your ad choices. Visit megaphone.fm/adchoices

Cancer is among the most common and feared diseases in the modern world. Dr. Selwyn Vickers—president and CEO of Memorial Sloan Kettering Cancer Center—joins host Mark Labberton to discuss how precision oncology, data, and faith are transforming cancer treatment. A distinguished cancer surgeon and pancreatic cancer researcher, Vickers explains how groundbreaking advances in genomics, immunotherapy, and AI are transforming once-lethal diagnoses into survivable and even chronic conditions. Together, they explore not only the cutting-edge science of cancer care but also the spiritual, emotional, and social dimensions that affect every patient and caregiver. Resonating with themes of suffering, hope, and resurrection, this conversation offers clarity, compassion, and courage for all who are affected by cancer—from those newly diagnosed, to medical professionals, to grieving families and curious listeners. Episode Highlights “We're getting to a point where we will, in the next five to seven years, have a much better chance to cure people—and to make pancreatic cancer a chronic illness.” “We are in what's somewhat coined the golden age of cancer research.” “Cancer is a disease that creates an existential threat in ways no other illness does.” “If a tumour forms, it means your body's immune system has made a social contract with the cancer.” “We changed the diagnosis in 10–12 percent of the patients who come to us—sometimes from cancer to no cancer.” “Cancer care is a team sport. And our patients often inspire us more than we help them.” Helpful Links & Resources Memorial Sloan Kettering Cancer Center BioNTech – creators of mRNA vaccines for COVID and cancer CAR T-Cell Therapy Overview (Cancer.gov) Tim Keller on cancer and hope Emma Thompson's Wit (HBO) BRCA1 and BRCA2 Genes and Cancer Risk MSK-IMPACT: Next-Gen Tumor Profiling About Selwyn Vickers Selwyn M. Vickers, MD, FACS, is the president and CEO of Memorial Sloan Kettering Cancer Center (MSK) and the incumbent of the Douglas A. Warner III Chair. He assumed the role on September 19, 2022. Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. He is a member of the National Academy of Medicine and the Johns Hopkins Society of Scholars. He has served on the Johns Hopkins School of Medicine Board of Trustees and the Johns Hopkins University Board of Trustees. Additionally, he has served as president of the Society for Surgery of the Alimentary Tract and the Southern Surgical Association. Vickers is the immediate past president of the American Surgical Association. He also continues to see patients. In 1994, he joined the faculty of the University of Alabama at Birmingham (UAB) as an assistant professor in the Department of Surgery, where he was later appointed to professor and the John H. Blue Chair of General Surgery. In 2006, Vickers left UAB to become the Jay Phillips Professor and Chair of the Department of Surgery at the University of Minnesota Medical School. Born in Demopolis, Alabama, Vickers grew up in Tuscaloosa and Huntsville. He earned baccalaureate and medical degrees and completed his surgical training (including a chief residency and surgical oncology fellowship) at the Johns Hopkins University. Vickers completed two postgraduate research fellowships with the National Institutes of Health and international surgical training at John Radcliffe Hospital of Oxford University, England. Vickers and his wife, Janice, who is also from Alabama, have been married since 1988. They have four children. Show Notes The ongoing threat and fear of cancer How Selwyn Vickers got into medicine Pancreatic cancer: Vickers's expertise “We are in what's somewhat coined the golden age of cancer research.” Sequencing the human genome “Is there a drug that might target the mutation that ended up creating your cancer?” Cancer as both a medical and existential diagnosis The revolution of precision oncology through human genome sequencing ”It takes a billion cells to have a one centimetre tumor.” Immunotherapy: checkpoint inhibition, CAR T-cell therapy, and vaccines Cellular therapy:   ”Taking a set of their normal cells and re-engineering them to actually go back and target and attack their tumors. … We've seen patients who had initially a 30 percent chance of survival converted to an 80 percent chance of survival.” “We know in many tumours there's something called minimal residual disease.” “Immunizing yourself against cancer is a significant future opportunity.” Managing the power of data with AI and computational oncology Cancer-care data explosion: the role of computational oncologists Cancer vaccines: breakthrough mRNA treatment for pancreatic cancer ”Didn't ultimately win. We had to suffer through her losing her life, but was so appreciative that she got much more than the six months she was promised.” Tumour misdiagnoses and the importance of specialized expertise Pancreatic cancer challenges: immune cloaking and late-stage detection In the past, one in four would die from the operation for removing pancreatic cancer Long-term survival Future of cancer detection: AI-based medical record analysis and blood biopsies More accurate blood tests to confirm conditions Using AI to select those who are high-risk for cancer Pastor Tim Keller died of pancreatic cancer. In the past, “your doctor … helped you learn how to die.” ”[God's] given man the privilege to discover those things that have been hidden. And over time we've gradually uncovered huge opportunities to impact people's lives.” The state of breast cancer research and treatment “If you get the diagnosis of breast cancer, you have a 90 percent chance to survive and beat it over a five-year period of time.” ”In general, we're in a great state of understanding how to treat breast cancer, how to detect it early, and then have selective and targeted mechanisms to prevent it from coming back.” Prostate cancer research and treatment Theranostics: using a specific antibody to target cancer cells specifically Pediatric cancer:  ”We actually treat more children for cancer than any hospital in America now, but in general, the survival for pediatric cancers is greater than 80 percent.” Emotional, psychological, and spiritual toll of cancer: importance of psycho-oncology How Sloan Kettering developed psycho-oncology to help cancer patients with mental and spiritual health Personal story: how a cafeteria worker empowers patients through food choices “We give back to them the right to choose what they get to have on their tray.” Cancer treatment is a team sport. Wit (film, Broadway play)—actress Emma Thompson plays a cancer patient studying the work of John Donne on death Socioeconomic and racial disparities in cancer care outcomes The healing role of community, support teams, and compassionate listening The importance of listening to cancer patients who are preparing to die The spiritual courage of patients and the transformative power of faith “Our patients often help us. We see the grace with which they often handle that journey.” The inspiration behind becoming a doctor: family legacy and human impact Terminal care: the sacred responsibility of walking with patients to the end Cancer research and treatment as a Christian vocation and expression of humanity Production Credits

Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications

Feeling overwhelmed by a never-ending task list? The most successful people don't do everything, they do the right things in the right order. This clip breaks down why mastering sequencing is the secret to growing in life and business without burning out. Learn to prioritize what truly matters, and build a schedule that honors both your hustle and your health. Longevity wins.Get access to our real estate community, coaching, courses, and events at Wealthy University https://www.wealthyuniversity.com/Join our FREE community, weekly calls, and bible studies for Christian entrepreneurs and business people. https://www.wealthykingdom.com/ If you want to level up, text me at 725-527-7783!--- About Ryan Pineda: Ryan Pineda has been in the real estate industry since 2010 and has invested in over $100,000,000 of real estate. He has completed over 700 flips and wholesales, and he owns over 650 rental units. As an entrepreneur, he has founded seven different businesses that have generated 7-8 figures of revenue. Ryan has amassed over 2 million followers on social media and has generat...

Movement in the music room doesn't have to be chaotic, and it definitely shouldn't start with a complex folk dance if your students have never done movement before! In this episode of That Music Podcast, Bryson breaks down a more intentional and developmentally appropriate approach to introducing movement in your classroom. You'll learn how to scaffold movement experiences so that your students can grow in confidence and coordination over time. From unstructured exploration to guided movement and finally structured activities, Bryson shares practical strategies to help students feel successful every step of the way. Whether you're new to using movement or just looking for a smoother process, this episode will help you set your students up for success, without the chaos. Episode Chapters: 0:00 Introduction 2:04 The 3 Steps Toward Structure 8:23 Takeaways Links and Resources: Elementary Newbie Guide Disabilities Guide Steady Beat Survival Guide Join That Music Teacher Community Have questions or want to share feedback? Reach out to us at hello@thatmusicteacher.com - we'd love to hear from you!

This one starts off strong — Bradshaw and Giana chat about house elves, some important announcements, and a very crucial update about Bradshaw's date with his dream guy (trust us, it's a story worth sticking around for).After the laughs, they dive into the real topic: Why Creative Sequencing Isn't Everything.They break down what creative sequencing actually is, why some teachers may lean heavily into it, and why it can sometimes be counterproductive. Giana and Bradshaw explore how sequencing shapes the overall experience of yoga — and how overly complex or random flows can sometimes feel chaotic, create confusion, and pull students away from the heart of the practice.They advocate for meeting students where they are, building them up thoughtfully, and recognizing that being in an overly anticipatory state (always wondering "what's next") can actually detract from the yoga itself. Instead of simply leaving students feeling good in the moment, they believe great sequencing should help students both feel and learn — ideally, it should do both.They also touch on essential topics like safety, accessibility, and the big question: Who is the creative sequencing really for — the student or the teacher?Expect real talk, real laughs, and a real reminder of what yoga is truly about.UPCOMING RETREAT:Starved Rock Yoga Retreat (JULY): https://www.cayayogaschool.com/starvedrockYoga Teachers Retreat: Costa Dulce, Nicaragua (MARCH 2026): https://cayayogaschool.com/pages/teachers-retreatBE PART OF OUR FUNNY FAM: https://www.cayayogaschool.com/communityPODCAST SUBSTACK: https://thefunnythingaboutyoga.substack.com/FOLLOW US:@thefunnythingaboutyoga @cayayogaschool @gianagambino @bradshawwishLINKS:https://www.cayayogaschool.com/https://www.gianayoga.com/ Hosted on Acast. See acast.com/privacy for more information.

This week I'm joined by Taylor Lorenz oftaylorstracks.com and @taylorstracks. Taylor is the creator of the yoga & travel site, Taylor's Tracks, a former full-time travel writer turned yoga teacher, mentor & trainer after taking her first YTT that sparked her self acceptance journey. We talk about ways to feel more confident, which limiting beliefs can keep us stuck in our teaching journeys and how accepting our bodies and modelling self-love is an essential part of being an inspiring Yoga teacher.Here are my links:Business coaching: www.amymcdonald.com.au/coachingCounselling: https://www.amymcdonald.com.au/counsellingCoaching training: https://www.amymcdonald.com.au/coachingtraining

This is a link post. Summary: The NAO will increase our sequencing significantly over the next few months, funded by a $3M grant from Open Philanthropy. This will allow us to scale our early-warning system to where we could flag many engineered pathogens early enough to mitigate their worst impacts, and also generate large amounts of data to develop, tune, and evaluate our detection systems. One of the biological threats the NAO is most concerned with is a 'stealth' pathogen, such as a virus with the profile of a faster-spreading HIV. This could cause a devastating pandemic, and early detection would be critical to mitigate the worst impacts. If such a pathogen were to spread, however, we wouldn't be able to monitor it with traditional approaches because we wouldn't know what to look for. Instead, we have invested in metagenomic sequencing for pathogen-agnostic detection. This doesn't require deciding what [...] --- First published: April 2nd, 2025 Source: https://forum.effectivealtruism.org/posts/AJ8bd2sz8tF7cxJff/scaling-our-pilot-early-warning-system Linkpost URL:https://naobservatory.org/blog/scaling-our-early-warning-system/ --- Narrated by TYPE III AUDIO. ---Images from the article:Apple Podcasts and Spotify do not show images in the episode description. Try Pocket Casts, or another podcast app.

Oxide is bringing up its next generation server. To discuss the (amazingly smooth) bringup process, Bryan and Adam were joined by members of the oxide team. Tales of adversity, re-work, un-re-work, and triumph!In addition to Bryan Cantrill and Adam Leventhal, we were joined by Oxide colleagues Nathanael Huffman, Ian Sobering, Matt Keeter, and Aaron Hartwig.We mentioned quite a few terms! Here's a helpful guide:Cosmo - Oxide's next-generation sled (currently in development) with an AMD Turin CPUGimlet - Oxide's current-generation sled with an AMD Milan CPUTurin - AMD Epyc 9005 SeriesMilan - AMD Epyc 7003 SeriesGenoa - AMD Epyc 9004 Series (Oxide chose to skip this generation)Sequencing - the precise control of when power rails are energized throughout a PCBSled - One of the (max 32) computers in an Oxide rack; a custom form-factor optimized for power and cooling efficiencyIBC - Intermediate Bus Converter (Our 54VDC -> 12VDC converter)RoT - Root of TrustSP - Service Processor, the small computer (running Hubris) that allows for low-level controlIgnition - An even lower-level control network for power management (including power of the SP)Ruby - The AMD reference platform (Oxide has used this to prepare Cosmo software in advance of bringup)DC-SCM - https://www.opencompute.org/documents/ocp-dc-scm-spec-rev-1-0-pdf and OpenCompute standard form factor.Grapefruit - OCP DC-SCM form-factor board with our SP, RoT, and FPGA on it, used to replace the OCP DC-SCM baseboard management controller in the Ruby platform.Cadence - Software Oxide previously used for PCB designAltium - Software Oxide now uses for PCB designHubris - Oxide's embedded operating system, run on the SP and RoTHumility - The Hubris debuggerPLM - Product Lifecycle Management – a class of software used for managing hardware BOMsBOM - Bill of Materials – the components required to build a hardware productRFK - Our colleague, Robert Keith (to distinguish him from our other colleague, Robert, and our former colleague, Keith)FPGA - Field Programmable Gate Array – Also referred to as “soft logic” – effectively programmable hardwareILA - Integrated Logic AnalyzerJTAG - A debugging interface for various processorsUART - A serial port or connectionFor previous tales from the bringup lab:Tales from the bringup labMore tales from the bringup labBringup Lab Chronicles: A Measurement Two Years in the MakingRaiding the MinibarIf we got something wrong or missed something, please file a PR! Our next show will likely be on Monday at 5p Pacific Time on our Discord server; stay tuned to our Mastodon feeds for details, or subscribe to this calendar. We'd love to have you join us, as we always love to hear from new speakers!

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Bispecific Antibodies for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (0:00) Clinical Data Available with Mosunetuzumab for R/R FL (1:54) Clinical Data Available with Epcoritamab for R/R FL (4:54) Clinical Data Available with Odronextamab for R/R FL (6:53) Clinical Considerations in Selecting Among Available Bispecific Antibodies for R/R FL (8:34) Practical Considerations in the Administration of Bispecific Antibodies (15:21) The Role of Vaccinations in the Prevention of Infections for Patients Receiving Bispecific Antibodies (18:34) Ongoing Clinical Trials Evaluating Bispecific Antibodies for FL (21:34) Case: A man in his late 60s with refractory FL who received mosunetuzumab monotherapy (24:24) Case: A woman in her late 50s with relapsed FL who received third-line epcoritamab monotherapy (30:14) Case: A man in his late 80s with a long-standing history of FL who received odronextamab in combination with a second novel bispecific antibody (33:48) CME information and select publications

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.

Alex Levin is the cofounder and CEO of Regal, a platform for AI phone agents. They've raised $82M from amazing investors such as Emergence Capital.Alex's favorite book: The PayPal Wars (Author: Eric M. Jackson)(00:01) Introduction(02:37) Evolution of customer contact tools and legacy players(06:02) Launching Regal: Origin story and early challenges(08:41) MVP strategy and problems worth solving(11:46) Lessons from 0 to 10 customers: Growth mistakes and hiring(16:13) Ideal early-stage team construction and hiring philosophy(19:06) Sequencing hires as company scales(20:58) What makes a good investor and how to leverage them(25:42) Best and worst experiments while building Regal(29:04) Internal use of AI at Regal across teams(31:49) The future of AI phone agents and near-term blockers(34:13) Rapid Fire Round--------Where to find Alex Levin: LinkedIn: https://www.linkedin.com/in/alexlevin1/--------Where to find Prateek Joshi: Newsletter: https://prateekjoshi.substack.com Website: https://prateekj.com LinkedIn: https://www.linkedin.com/in/prateek-joshi-91047b19 X: https://x.com/prateekvjoshi 

In this eye-opening episode of The Joe Cohen Show, Joe sits down with microbiologist and biotech entrepreneur Kiran Krishnan to dismantle the myths and marketing hype surrounding microbiome testing. Drawing parallels between the DNA and microbiome industries, they expose the scientific shortcuts, technological flaws, and misleading health claims being sold to consumers.Krishnan, the mind behind one of the few microbiome platforms used in published research, breaks down what a legitimate test looks like and why most tests on the market fall short, sometimes by as much as 70% in accuracy. The conversation also explores probiotics in depth, why strain specificity matters, and how consumers can make more informed decisions when navigating this complex and evolving space.Whether you're a health professional or someone trying to optimize your gut, this episode will help you separate science from sales.

予算カット、２年ルールWaiver、資産運用への影響、メールでのコミュニケーションなど。論文紹介は、実装が簡単な高速FLIMと、Sequeincing by expansion (4/9収録)Show Notes (番組HP):渦中のハーバード(pdf)コロンビアのNIHグラント停止Hiring Freeze Announcementデモに参加したらビザ停止Stand Up For ScienceTwitterで告知2年ルールのWaiver濱崎さん回401(k)iDeCoReddit: Fire Flow Chart Version 4.3Reddit: 401(k) max vs mortgage payment三権分立の憲法への反映はアメリカが先五十嵐さん回 1 2 3 4NSFはFellowshipを出す数が半分にRedditに降臨２ちゃんに柳沢先生ご本人登場マウスも毛むくじゃらにのプレプリント狼復活論文紹介論文１：Absolute measurement of fast and slow neuronal signals with fluorescence lifetime photometry at high temporal resolutionSabatini (弟) ラボ安田さん回Jablonski図Time DomainでのFLIM計測のわかりやすい図 (pdf, これの7ページ目)Frequency Domainとの比較に使った図 (pdf)注:PMTからのシグナルも位相をズラすと返答してしまっていますが間違いです。(萩)Fiber Photometry を流行らせたのはDラボロックインアンプFLIM用のcAMPセンサーWash UのYao ChenCholinergicセンサーFLIM転用Becker & HicklのFLIMInstant FLIM前にSabatiniラボのプレプリントを読んだ回David AndersonのState論文、たとえば 1 2 3脳の温度は結構変わるpHも睡眠とかで変わる未来予想回齋藤さん回 1 2 3論文２：Sequencing by Expansion (SBX) – a novel, high-throughput single-molecule sequencing technologyナノポアレビューDpo4CMOSによる並列化の例ONTのNanoporeONTを使ったリード精度benchmark研究階段状の建物元根さんProtein Sequencing日本語解説本社のプレスリリース動画Editorial Notes:The Apprentice の参加者になった気分です (脇)大学の自治を守るのは大変重要ですが、ファカルティは大学側の政府への抗議をどう受け取ってるんでしょう。しかし、9 billionだったり2.2 billionだったり、桁が大き過ぎてもうよくわからなくなってきました(萩)

This podcast episode features experts Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gloria Iacoboni,... The post Sequencing therapies in R/R NHL: immunotherapy in DLBCL, BTKis in MCL, & more! appeared first on VJHemOnc.

TikTok Flat Earthers; News Items: De-extincting the Dire Wolf, What Experts Think About AI, Planned Obsolescence, VR Touch Sensory; Who's That Noisy; Your Questions and E-mails: SNPs vs Sequencing; Science or Fiction

TikTok Flat Earthers; News Items: De-extincting the Dire Wolf, What Experts Think About AI, Planned Obsolescence, VR Touch Sensory; Who's That Noisy; Your Questions and E-mails: SNPs vs Sequencing; Science or Fiction

Dan & Billy welcome back longtime friend & Nostalgia Test Podcast Allstar Jeremy Madson to put Metallica's 90s MTV Era to the ultimate test—THE NOSTALGIA TEST! “We're on the reverse trajectory of Kiss. Right? Because KISS took the makeup off in the nineties and Metallic put it on.” -Jeremy Madson The boys continue the Metallica Eras journey Nostalgia Test Podcast Metalheads with the controversial 90s studio albums The Black Album, Load, & Reload, also known as the MTV era & the Jason Newstead. Dan, Billy, & Jeremy headbang down memory lane and talk about hearing these albums for the first time, the weird transition from the thrash era to whatever this mid-life metal crisis was, the shift in Metallica's musical style, the peculiar cover art for Load & Reload, and production choices. They go track-by-track and create a 10-track merged version of Load & Reload called Unload, which you can listen to here. In the end, the guys rank the 90s era albums.   If you're a Metallica nerd, this episode is for you. If you're not, listen anyway and give it 5-stars. Listen to Unload on Spotify! Email us (thenostalgiatest@gmail.com) ranking so we can share them on the next Metallica episode!    APPROXIMATE RUN OF SHOW: 00:00 Introduction to the Metallica Nostalgia Test 00:37 Recap of Previous Episodes and Albums 01:17 The Nineties Era: MTV and Jason Newstead 01:55 Metallica's Costume Era and Music Videos 03:23 High School Memories and Metallica's Influence 09:26 The Black Album: A Turning Point 19:24 Load and Reload: The Controversial Albums 40:51 Guitar Solos and Bob Rock's Influence 41:58 Debating the Merits of 'Bleeding Me' 42:34 Critiquing 'Cure' and Other Tracks 44:24 Discussing 'Wasting My Hate' 46:38 Country Influences in Metallica's Music 47:11 The Controversial 'Mama Said' 47:46 Evaluating 'Thorn Within' and 'Ronnie' 50:42 The Outlaw Torn and Album Reflection 51:10 Nostalgia Test: Does 'Load' Hold Up? 55:50 Comparing 'Load' to Other Albums of the Era 58:13 Introduction to 'Reload' and Its Reception 58:48 Lead Singles and Album Strategy 01:00:35 Track-by-Track Breakdown of 'Reload' 01:09:32 The Unforgiven II: A Sequel Song 01:13:29 Mixed Reviews on 'Better Than You' and 'Slither' 01:14:56 Debating the Middle Part of the Song 01:15:25 Critiquing the Lyrics and Vocals 01:15:49 Generic Hard Rock and Stoner Rock Comparisons 01:16:39 Discussing 'Where the Wild Things Are' 01:17:05 Lars' Dad's Brutal Honesty 01:17:44 Evaluating 'Prince Charming' 01:18:07 The Unmemorable Riffs 01:20:33 The Irish Bar Drinking Song Vibe 01:21:20 WWE and 'Attitude' 01:21:27 The Lengthy 'Fixer' 01:23:01 Reload Exhaustion and Nostalgia 01:29:50 Ranking and Sequencing the Best Tracks 01:43:45 Final Thoughts and Ranking the Era     Contact/Book The Nostalgia Test Podcast! If you had a great time listening to The Nostalgia Test Podcast and want to book us on your next podcast or have perform at your themed party, or have us host a special event, fill out the form below and LET'S GET NOSTALGIC! We can do so many fun Nostalgic Events! Podcast Guest Appearances Themed Parties Hosting Screenings Corporate Events Reunions Weddings Birthday Parties Trivia The Nostalgia Test Podcast will create a personalized Nostalgic experience for any occasion! Email us at thenostalgiatest@gmail.com or fill out the Google Form below to get the process started. We're open to in-person and virtual events. Pricing may vary depending on the details of your event/party.   LET'S GET NOSTALGIC!       Keep up with all things The Nostalgia Test Podcast on Instagram | Substack | Discord | TikTok | Bluesky | YouTube | Facebook   The intro and outro music ('Neon Attack 80s') is by Emanmusic. The Lithology Brewing ad music ("Red, White, Black, & Blue") is by PEG and the Rejected    

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Aman Chauhan, a medical oncologist specializing in neuroendocrine tumors from Sylvester Comprehensive Cancer Center in Miami. As of April 2025, the oncology landscape has seen 10 new FDA approvals, including the recent approval of cabozantinib for neuroendocrine tumors based on the CABINET study. The discussion dived deep into the implications of this approval, the study design, and how cabozantinib fits into the treatment landscape for both pancreatic and extra-pancreatic neuroendocrine tumors. Key topics covered in this episode include: •⁠  ⁠The evolution of treatment options for neuroendocrine tumors •⁠  ⁠Insights into the CABINET study design and results •⁠  ⁠Sequencing treatment options for patients with neuroendocrine tumors •⁠  ⁠Side effects and management strategies for cabozantinib •⁠  ⁠The importance of personalized treatment approaches in oncology Join us as we explore the exciting advancements in neuroendocrine tumor management and what they mean for patients and oncologists alike. Don't forget to like, subscribe, and check out our other discussions on FDA approvals, toxicity management, and conference highlights! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on oncology insights!

Sequencing with the #1 Virtual Reality Hitting Tool

Send us a textBRAND NEW BOOK - The Daily Bible Devotional Volume 2 (Acts - Ephesians) is now available on Amazon. We hope this becomes a great daily tool in engaging with the New Testament, one chapter at a time. Amazon - (paperback, hardcover, and Kindle)Sponsors:  Jon Cunningham, Owner, Cunningham Financial GroupWebsite:  www.cunninghamfinancialgroup.com   Phone:  205-326-7364Tyler Cain, Senior Loan Officer, Statewide MortgageWebsites: https://statewidemortgage.com/https://tylercain.floify.com/Phone: 813-380-8487Here's the Exercise of the Episode:Answer four questions:- Why are you a Christian?- Why do you go to worship?- Why do you treat everyone with kindness?- Why do you abstain from sexual immorality?First - Answer each question starting with JESUSSecond - Answer each starting with OTHERSFinally - Answer each starting with YOURSELFThis is the way to process and prioritize all we do.Sequencing is Important: J.O.Y.  

Welcome to the CavasShips Podcast with Christopher P. Cavas and Chris Servello…a weekly podcast looking at naval and maritime events and issues of the day – in the US, across the seas and around the world. This week…keeping the Navy's fighting ships in fighting trim is all about sequencing the maintenance correctly.  Robb Chadwick, a retired flag officer with extensive at sea experience explains how thoughtful sequencing of maintenance can make all the difference in saving time and money.  Please send us feedback by DM'ing @CavasShips or @CSSProvision or you can email chriscavas@gmail.com or cservello@defaeroreport.com.

What are the personalized medicine and market lessons from the fall of 23andMe? David W. Johnson and Julie Murchinson perform a postmortem on the failure of the direct-to-consumer genetic testing company on “Sequencing the Fallout from the 23andMe Collapse,” the new episode of the 4sight Health Roundup podcast, moderated by David Burda. Listen.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

Michael Reinking joins Diane King Hall at the NYSE set to discuss this week's volatility ahead of April 2nd. With tariff deadlines looming and investors positioning for market swings, Michael sees flows moving from high growth names into energy, materials, staples and healthcare. Looking forward, Michael says tariff impact will be a major theme for the upcoming earnings season.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

Josh Bowen is the founder of Astria, the easiest way to deploy decentralized rollups. Why you should listen In this conversation, Josh Bowen, co-founder of Astria, discusses the evolution and significance of decentralized sequencing in the blockchain ecosystem. He shares insights on the current state of rollups, the impact of regulatory changes, and the future of decentralized finance (DeFi). Josh also introduces Astria's new rollup, Flame, and emphasizes the importance of user experience in attracting wider adoption of DeFi. The discussion touches on the existential questions surrounding decentralization and the future of blockchain technology. Astria is building the shared sequencing layer for modular blockchains — an innovative approach designed to supercharge rollup scalability while preserving decentralization. By decoupling sequencing from execution, Astria gives developers the ability to launch fast, censorship-resistant rollups without needing to bootstrap their own validator sets or trusted sequencers. The core idea? Shared sequencing as a public good — one decentralized sequencer network serving many rollups. Under the hood, Astria's shared sequencer is powered by CometBFT and integrated with Celestia for data availability. This enables near-instant transaction inclusion and atomic cross-rollup composability, solving some of the most pressing coordination problems in the modular stack. Developers can spin up an Astria-integrated rollup with tools like Rollkit and benefit from out-of-the-box speed, fairness, and security. In a world of rollup proliferation, Astria is carving out the infrastructure to make modular chains truly interoperable and decentralized. Supporting links Stabull Finance Astria Andy on Twitter  Brave New Coin on Twitter Brave New Coin If you enjoyed the show please subscribe to the Crypto Conversation and give us a 5-star rating and a positive review in whatever podcast app you are using.

- Overview of Breast Cancer in Younger Women, Including Diagnosing, Staging & ER, PR, HER2 Status - Unique Issues for Younger Women Living with Breast Cancer - Precision Medicine & Sequencing of Treatment - Genetic Testing, Including BRCA Testing - What Informs Treatment Decisions & Options - Understanding Your Pathology Report - Updates on Clinical Trials: How Research Increases Treatment Options - Tools that Help Indicate What Types of Treatment Are Indicated: Surgery, Chemotherapy & Radiation Treatments - Questions to Ask Your Health Care Team - Managing Side Effects, Symptoms, Discomfort & Pain - Quality-of-Life, Including Sexual Health, Pregnancy & Fertility Issues - Practical & Emotional Coping Tips - Questions for Our Panel of Experts

- Overview of Breast Cancer in Younger Women, Including Diagnosing, Staging & ER, PR, HER2 Status - Unique Issues for Younger Women Living with Breast Cancer - Precision Medicine & Sequencing of Treatment - Genetic Testing, Including BRCA Testing - What Informs Treatment Decisions & Options - Understanding Your Pathology Report - Updates on Clinical Trials: How Research Increases Treatment Options - Tools that Help Indicate What Types of Treatment Are Indicated: Surgery, Chemotherapy & Radiation Treatments - Questions to Ask Your Health Care Team - Managing Side Effects, Symptoms, Discomfort & Pain - Quality-of-Life, Including Sexual Health, Pregnancy & Fertility Issues - Practical & Emotional Coping Tips - Questions for Our Panel of Experts

- Overview of Breast Cancer in Younger Women, Including Diagnosing, Staging & ER, PR, HER2 Status - Unique Issues for Younger Women Living with Breast Cancer - Precision Medicine & Sequencing of Treatment - Genetic Testing, Including BRCA Testing - What Informs Treatment Decisions & Options - Understanding Your Pathology Report - Updates on Clinical Trials: How Research Increases Treatment Options - Tools that Help Indicate What Types of Treatment Are Indicated: Surgery, Chemotherapy & Radiation Treatments - Questions to Ask Your Health Care Team - Managing Side Effects, Symptoms, Discomfort & Pain - Quality-of-Life, Including Sexual Health, Pregnancy & Fertility Issues - Practical & Emotional Coping Tips - Questions for Our Panel of Experts

Success isn't about tackling every problem at once—it's about mastering the art of sequencing and managing your schedule. Learn how to prioritize effectively, focus on what truly matters, and create a sustainable routine for long-term success.---If you want to level up, text me at 725-527-7783! Get access to our real estate community, coaching, courses, and events at Wealthy University https://www.wealthyuniversity.com/Join our FREE community, weekly calls, and bible studies for Christian entrepreneurs and business people. https://www.wealthykingdom.com/--- ---About Ryan Pineda: Ryan Pineda has been in the real estate industry since 2010 and has invested in over $100,000,000 of real estate. He has completed over 700 flips and wholesales, and he owns over 650 rental units. As an entrepreneur, he has founded seven different businesses that have generated 7-8 figures of revenue. Ryan has amassed over 2 million followers on social media a...

In our new series Insights, go inside Class 6 of NEXT PM. In this short segment, Taylor will highlight the importance of work sequencing - the critical role of dependency mapping as well as potential bottlenecks to be aware of. Enjoy the Insights and #BeNEXT.To learn more about NEXT PM, please visit our website at ⁠www.nextleadershipacademy.org/pm

In the same way that genome sequencing determines the genetic makeup of an organism, Bryan Johnson — the investor and founder behind the Don't Die movement – wants to start “foodome” sequencing. Learn more about your ad choices. Visit podcastchoices.com/adchoices

View all cards mentioned in this episodeAndy, Anthony, and Zach talk about improving as a Magic player, building a community and how they try to balance the two. They talk about the challenges of fostering positive social standards and how that can conflict with trying to improve at a competitive game.Discussed in this episode:The Null HypothesisCheck us out on Twitch and YouTube for paper Cube gameplay.You can find the hosts' Cubes on Cube Cobra:Andy's “Bun Magic” CubeAnthony's “Regular” CubeYou can find both your hosts in the MTG Cube Talk Discord. Send in questions to the show at mail@luckypaper.co or our p.o. box:Lucky PaperPO Box 4855Baltimore, MD 21211If you'd like to show your support for the show, please leave us a review on iTunes or wherever you listen.Musical production by DJ James Nasty.Timestamps0:00 - Intro2:22 - Balancing Developing Skill as a Player with Building a Community9:17 - The Nuanced, Complex Social Dynamics of Playing Magic12:57 - The Factors that Contribute to a Playgroup's Vibe27:20 - The Tension Between Improvement and Community32:54 - The Value of Shared Expectations in a Community40:45 - On “Take Backs” and Learning from Your Mistakes1:03:07 - Zach asks Andy and Anthony if they're satisfied with their level of competitiveness1:06:42 - Sequencing speed round

duckDNA recently concluded its second season, which brought continued enthusiasm from hunters and several never-before-seen hybrids! On this episode, Dr. Mike Brasher is joined by conservation science assistants, Kayci Messerly and Katie Tucker, and Dr. Phil Lavretsky to share initial results from season 2 while discussing genetic mysteries uncovered through the analysis of several unique hybrid ducks. Also discussed are behind-the-scenes interactions with participating hunters and the potential future of duckDNA. Thanks to hunters for their support and participation and a special thanks to our year 2 funding partners -- Pinola Conservancy, Rice Pond Preserve, and Brian Hornung.Listen now: www.ducks.org/DUPodcastSend feedback: DUPodcast@ducks.org

I'm joined by Christian Henry, CEO of PacBio, a company leading the way in high-accuracy long-read sequencing. We break down what that means in simple terms, how this technology is helping families solve their diagnostic odyssey, and why some genetic tests miss key information that PacBio can detect. Plus, if you've already had whole genome sequencing without finding an answer, Christian explains why it might be time to take another look. We also dive into the future of genetic testing, what needs to change for sequencing to become a routine part of medical care, and how families and advocates can help drive progress forward. This episode is all about hope, science, and the relentless pursuit of answers. Happy Rare Disease Day, and thank you for being part of this incredible community! Topics Covered: ✅ What is long-read sequencing, and how is it different from traditional genetic testing? ✅ How PacBio's technology is solving rare disease mysteries faster and more accurately. ✅ Why some families don't get answers from whole genome sequencing—and why they should consider trying again. ✅ The biggest barriers to making genetic testing more accessible and routine in rare disease care. ✅ How long-read sequencing could help lead to future treatments, not just diagnoses. ✅ What the next five years of genomic sequencing could look like. ✅ How rare disease families and advocacy groups can collaborate with PacBio to accelerate discoveries. Resources & Links:

Featuring slide presentations and related discussion from Prof Martin Hutchings, Dr Manali Kamdar, Dr Matthew Lunning and Prof Gilles Salles, including the following topics: Evolving Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (0:00) Case: A 61-year-old man with Stage IV non-GCB DLBCL receives R-CHOP but experiences disease progression 8 months later (30:39) Case: A 68-year-old man with double-hit DLBCL who experiences disease progression on chemotherapy and second-line CAR T-cell therapy receives glofitamab (39:22) Incorporation of Bispecific Antibody Therapy into DLBCL Management — Prof Hutchings (45:25) Case: A 42-year-old man with progressive DLBCL refractory to 2 lines of therapy receives glofitamab with a durable response (1:07:30) Case: An 81-year-old woman with multiregimen-refractory DLBCL experiences a prolonged response to epcoritamab (1:14:25) Case: A 69-year-old man with follicular lymphoma transformed to DLBCL and refractory to 3 lines of treatment receives glofitamab (1:21:48) Selection and Sequencing of Other Available Therapies for Relapsed/Refractory (R/R) DLBCL — Prof Salles (1:24:37) Case: An 82-year-old woman with follicular lymphoma transformed to DLBCL receives tafasitamab/lenalidomide (1:42:05) Case: A 69-year-old man with urinary bladder carcinoma and recurrent GCB DLBCL receives loncastuximab tesirine (1:46:26) Promising Investigational Approaches for Patients with R/R DLBCL — Dr Lunning (2:00:37) Case: An 80-year-old woman with multiregimen-refractory GCB DLBCL seeks treatment requiring minimal clinic visits and receives loncastuximab tesirine (2:15:59) Case: A 54-year-old man with primary refractory non-GCB DLBCL receives CAR T-cell therapy, and follow-up imaging on day 29 demonstrates a Deauville score of 4 (2:25:22) CME information and select publications

What if the best approach to health wasn't about choosing between Eastern and Western medicine, but embracing both? This episode explores how these two medical philosophies complement each other—Eastern medicine focuses on prevention, balance, and holistic well-being, while Western medicine excels in emergency care, diagnostics, and treating acute conditions. The discussion highlights how integrating both perspectives can lead to a more comprehensive and empowered approach to personal health.Michael shares real-life examples, including a woman who avoided Western intervention and tragically passed away after her appendix ruptured. They emphasize that while Eastern medicine provides powerful preventative practices like acupuncture, Ayurveda, and herbal remedies, there are times when Western treatments are essential for survival. The conversation also explores the evolving acceptance of holistic healing practices, as yoga, meditation, and herbal medicine become increasingly recognized for their benefits.The episode encourages listeners to take responsibility for their health by tuning into their bodies, using preventative self-care, and remaining open to both scientific and traditional healing methods. By blending modern medicine with ancient wisdom, individuals can create a personalized, integrative approach to long-term wellness.Episode Chapters:00:00:00 - Integrating Eastern and Western Medicine00:02:36 - Balancing Eastern and Western Medicine00:05:07 - Integrating Eastern and Western Medicine00:07:28 - Integrating Eastern and Western Medicine00:10:49 - The Strengths and Limitations of Western and Eastern Medicine00:12:43 - Integrating Eastern and Western Approaches to Medicine00:16:45 - Balancing Eastern and Western Approaches to Healing00:19:51 - Balancing Eastern and Western Approaches to Wellness00:22:32 - Balancing the Body Through Preventative Care and Herbal Medicine00:25:37 - Dealing with Unexpected Stomach Pain00:28:24 - Integrating Eastern and Western Approaches for Holistic Health00:31:18 - Blending Eastern and Western Medicine00:34:02 - Exploring Yoga Interests and Connections—-------—-------—-Michael Henri's Instagram:https://www.instagram.com/michaelyoga.pt/ Going Pro Yoga's Instagram: https://www.instagram/com/goingproyoga/—-------—-------—-Other Mentions:Book: Encyclopedia of Herbal Medicine---About Going Pro Yoga:At Going Pro Yoga, we help yoga teachers become even better by teaching them new skills and giving them the tools they need to make their yoga classes safe, fun, and special for everyone.**Right now you can try Going Pro Yoga FREE for 7-days and sample: All Tools Needed to Master Cueing, Sequencing, and Alignment Video Library of over 75 fully Sequenced Classes, Sequence Chunks, and Flows FIRST EVER Yoga Cueing System with Over 160 poses and Hundreds of Variations Wisdom Talks from over 20,000 Hours of Teaching Experience Anatomy and Injury Prevention as it relates to Yoga.To Learn More, Visit Going Pro Yoga, and⁠⁠⁠Start your 7-Day Free Trial⁠⁠⁠!For more information about in-person trainings in Bali,⁠⁠https://www.elementsofpoweryoga.com/advancedtrainings⁠⁠